The chimeric BCR–ABL oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). BCR–ABL contains nuclear import and export signals but it is localized only in the cytoplasm ...

The results of this study support the role for this drug as first-line therapy for CML. Nilotinib is more selective at inhibiting BCR-ABL than any other protein tyrosine kinases, and the ...

However, neither the Philadelphia chromosome nor BCR-ABL is pathognomonic of CML, as they are present in other human hematologic malignancies. p210 BCR-ABL is found in 95% of patients with CML ...

1. How to Track Progress Through Regular Monitoring? Regular BCR-ABL testing is key to managing CML. These tests measure the BCR-ABL protein level which will help you track your treatment progress.

Therefore, it is necessary to develop more effective Abl TKIs that are both orally bioavailable and more potent than imatinib in blocking Bcr–Abl kinase activity, including variants with point ...